The rising burden of Alzheimer’s disease across the United States, Canada, and Mexico is accelerating demand for advanced therapeutics, innovative biologics, and early-stage treatment solutions. Increasing life expectancy and the expanding geriatric population are contributing to a higher prevalence of neurodegenerative disorders, encouraging pharmaceutical companies to strengthen...